Parvovirus Infection

oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

Synonyms: erythema infectiosum, slapped cheek disease, slapped cheek syndrome, fifth disease, parvovirus B19

Parvovirus B19 is a common infection, usually presenting as erythema infectiosum in children. There is a wide range of potential consequences of parvovirus B19 infection. These extend from minor febrile illness to erythema infectiosum (fifth disease, slapped cheek syndrome), a generalised rash illness clinically indistinguishable from rubella, aplastic crises in patients with increased red cell turnover, arthropathy, and persistent infection in the immunocompromised. It may also cause fetal loss or fetal hydrops and so detection in pregnancy is important for monitoring and possible treatment.

Parvoviruses are among the smallest DNA-containing viruses known to infect mammals (hence the name parvus, which is Latin for small). The only parvovirus known to be pathogenic in humans is parvovirus B19, discovered in 1974 whilst testing for serum hepatitis B antigens. It was so called because it occurred in serum sample 19, panel B. It is a single-strand DNA virus with no lipid coat, which makes it very resistant to the normal means of killing viruses, such as disinfectants and freezing.

Parvovirus is an extremely common infection. It most commonly occurs in children aged between 3-15 years. The most common clinical encounter with parvovirus B19 is as the causative agent of erythema infectiosum (fifth disease). This infection is not a notifiable disease.

Approximately 50-60% of individuals in the UK will have already been infected with parvovirus B19 by the time they reach adulthood.[1] Infection in temperate countries like the UK is seasonal, with increases in infection in spring and early summer, with additional increases in incidence occurring every 3-4 years. There was an increase in parvovirus B19 activity in 2012 compared to the previous two years.[2] 

Save time & improve your PDP on Patient.co.uk

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »

Infectivity and transmission

  • Transmission is usually via respiratory secretions, but it can also be passed on via blood transfusion, bone marrow transplant, other blood products (but not intramuscular immunoglobulins), and from mother to baby via the placenta.
  • The incubation period for clinical erythema infectiosum is 4-20 days before the rash develops. The illness is infective from 10 days pre-rash until the onset of the rash. Once the rash appears, it is no longer infectious.
  • Infectivity is medium. For susceptible individuals during epidemics, the attack rate is 50% for household contacts and schoolchildren, and 30% for teachers.[3]
  • One attack confers lifelong immunity.
  • Note:
    • Patients with aplastic crisis (see 'Complications', below) are highly infectious.
    • Immunocompromised patients may remain infectious.

It may be asymptomatic (about 25% of infections) or it may present only with nonspecific coryzal symptoms (common).

Erythema infectiosum: this is also called 'fifth disease' because it is the fifth of the classic exanthems.

parvoB19l

Prodromal symptoms usually start around a week following exposure to parvovirus B19. They are usually mild and may include headache, rhinitis, sore throat, low-grade fever and malaise. Less commonly, nausea, diarrhoea, abdominal pain or arthralgia may develop.

Following the prodromal phase, patients are usually symptom-free for around 7-10 days and then the classic 'slapped cheek' rash usually appears as erythema on the cheeks, sparing the nose, perioral and periorbital regions. This disappears after 2-4 days.

About 1-4 days after the facial rash appears, an erythematous macular/morbilliform rash develops on the extremities, mainly on the extensor surfaces. It is usually not itchy in young children, but may be itchy in older children and adults. This gradually fades over the subsequent 3-21 days, but may recur in reaction to various stimuli such as exercise, heat and sunlight.

Arthropathy

  • May present as symmetrical arthropathy, affecting the hands, wrists, knees and ankles.
  • The symptoms usually resolve within a few days but in some cases persist for two months or longer.
  • An acute arthropathy is more common in adults than in children and it is more common in women.
  • The joint pain usually worsens throughout the day.

Intrauterine infection

See 'Parvovirus B19 in pregnancy', below.

Haematological conditions

Infection in immunodeficient patients

  • Parvovirus B19 can cause immunocytopenia in immunocompromised patients.
  • These patients may be unable to eradicate the infection, due to inadequate levels of IgM. They may remain infectious, yet test negative to IgM serology. Detection of the infection by alternative assays is necessary and is important for infection control.
  • Meningoencephalitis can occur with acute parvovirus infection.

Other complications

  • Rarely, parvovirus B19 has been linked to hepatitis, myocarditis, meningitis, encephalitis and peripheral neuropathy.

Erythema infectiosum

  • Rubella (look for suboccipital lymphadenopathy).
  • Measles (look for Koplik's spots on buccal mucosa).
  • Scarlet fever (look for strawberry tongue).
  • Roseola infantum.
  • Drug eruptions.
  • Other infections can present with rash, including meningitis and septicaemia.

Older children or adults with arthropathy and rash

  • Acute rheumatic fever.
  • Allergic hypersensitivity reaction.
  • Classic viral exanthems.
  • Disseminated gonococcal infection.
  • Epstein-Barr virus.
  • Hepatitis (parvovirus may cause transient elevations in liver enzymes).
  • Lyme disease.
  • Rheumatological disorders.

Investigations are not necessary in patients with uncomplicated erythema infectiosum. However, if the clinical scenario requires confirmation of diagnosis (eg, pregnancy, immunocompromised patients, aplastic crisis, arthropathy), the following may be helpful:

  • B19-specific IgM - a positive screen indicates current or recent infection. Note: immunocompromised patients may be unable to make sufficient IgM and may test negative; they will need other tests.
  • B19-specific IgG indicates immunity - it usually appears two weeks after infection and persists for life. IgG may also detect seroconversion in immunocompromised patients.
  • Polymerase chain reaction (PCR) - for the specific detection of parvovirus B19.

For healthy and non-pregnant patients, only symptomatic treatment and explanation is needed.

To prevent transmission:

  • Advise patients to avoid contact with those at risk of complications: pregnant women, immunocompromised patients and those with haematological conditions. If contact does occur, these people should be advised to see their doctor.
  • Within households and in institutions, transmission is difficult to prevent, but hand washing is recommended.
  • For erythema infectiosum, the diagnostic features appear after the period of infectivity has passed, so exclusion from school has no effect on transmission.
  • Erythema infectiosum: this is a self-limiting condition in immunocompetent patients.
  • Pregnancy: see 'Parvovirus B19 in pregnancy', below.
  • Arthropathy: there are no long-term sequelae.
  • Transient aplastic crisis: this is usually transient, lasting no more than two weeks in otherwise healthy individuals, and rapidly responds to treatment if required.
  • Immunocompromised patients: the treatment of pure red cell aplasia with immunoglobulin is frequently ameliorative and often curative.

Epidemiology, transmission and risks[1] 

  • Pregnant women who develop erythema infectiosum have a 30% chance of passing it on to their unborn baby and a 5-10% chance of fetal loss. During the first trimester the risk of fetal complications is heightened.
  • Although the maternal symptoms of the virus are usually short-lived, additional fetal complications that can occur include hydrops fetalis, hepatitis, severe anaemia, inflammation of the heart muscle and cardiac failure.
  • Maternal infection in the first trimester is associated with a risk of fetal death of 19%. A gestational age of 13-20 weeks is associated with a 15% chance of fetal death and this falls to 6% after 20 weeks.
  • Identification of parvovirus B19 infection in a pregnant woman is important, as parvovirus infection in the first half of pregnancy may cause intrauterine death and fetal hydrops.
  • Permanent congenital abnormality and/or congenital anaemia have also been identified as rare consequences of intrauterine infection.
  • Maternal asymptomatic parvovirus B19 infection is at least as likely to infect and damage the fetus as symptomatic infection.
  • Diagnosis is important, as intrauterine transfusion of the fetus improves the outcome.

Investigation and management in pregnancy

General principles

  • All pregnant women who have a non-vesicular rash, or contact with someone suffering from a non-vesicular rash, should be investigated for parvovirus and rubella infection - irrespective of past history, previous serology or gestation.
    • Contact is defined as being in the same room for >15 minutes or face-to-face contact; however, for parvovirus, this is probably over-cautious, the main risk of infection being from household contacts or prolonged occupational contact.
  • The IgM result confirms or excludes infection in the 4 weeks prior to the sample. This also means that parvovirus infection cannot be excluded if investigation starts >4 weeks after onset of the rash.

When/what to test

  • Test for parvovirus B19 (and rubella) IgM and IgG as soon as possible after contact with, or symptoms of, a rash illness. Include details of dates of illness/contact, details of rash, gestation, etc.
    • Positive IgG with negative IgM will confirm immunity and the patient can be reassured.
  • If IgM is detected, but IgG is not detected, a further sample should be taken immediately. If the repeat sample is positive for IgM further testing, confirmation by alternative assay is required - eg, detection of high titre B19 virus DNA or IgG seroconversion using an antenatal booking blood (discuss with microbiologist).
  • If neither IgG nor IgM is detected, a further sample should be tested one month later.
    • If both are negative, the woman can be reassured that she has no evidence of parvovirus infection, but is susceptible.

Management of confirmed parvovirus infection in pregnancy[6] 

  • When serology shows potential for early infection with parvovirus B19, the patient should be referred to a fetal medicine unit capable of fetal blood sampling and intravascular transfusion.
  • Serial ultrasound scanning of the fetus and Doppler assessment are usually undertaken.
  • Following confirmation of parvovirus B19 in a pregnant woman presenting with hydrops fetalis, referral to a Regional Fetal Medicine Unit is recommended if this has not already occurred. If a fetal blood sample is collected then examination by quantitative PCR to confirm fetal infection should be arranged.
  • Fetal blood sampling and intrauterine transfusion of erythrocytes may be undertaken.
  • Early delivery of the baby may be necessary if it is near full term (amniocentesis for lung maturity and treatment with corticosteroids may be indicated).
  • There is currently no licensed vaccine for parvovirus B19.
  • Screening of donated blood components before transfusion for patients with sickle cell disease and other congenital anaemias, immunocompromised hosts, and women during pregnancy.
  • Healthcare workers should not be caring for patients if they have flu-like symptoms, a fever or a rash. This is particularly important if they are caring for patients at risk from parvovirus B19, ie pregnant women, immunocompromised patients and those with hereditary anaemias.
  • Children with parvovirus infectiosum do not need to stay off school or nursery, as once they have the rash they are no longer infectious.

Further reading & references

  1. Lamont RF, Sobel JD, Vaisbuch E, et al; Parvovirus B19 infection in human pregnancy. BJOG. 2011 Jan;118(2):175-86. doi: 10.1111/j.1471-0528.2010.02749.x. Epub 2010 Oct 13.
  2. Increased parvovirus B19 activity in England and Wales; Health Protection Report Vol 6, No. 24, Health Protection Agency, June 2012
  3. Stelma FF, Smismans A, Goossens VJ, et al; Occupational risk of human Cytomegalovirus and Parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence. Eur J Clin Microbiol Infect Dis. 2009 Apr;28(4):393-7. doi: 10.1007/s10096-008-0635-y. Epub 2008 Oct 11.
  4. de Jong EP, Walther FJ, Kroes AC, et al; Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn. 2011 May;31(5):419-25. doi: 10.1002/pd.2714. Epub 2011 Feb 24.
  5. Guidance on Viral Rash in Pregnancy; Health Protection Agency (January 2011)
  6. Parvovirus B19 infection; NICE CKS, April 2010

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Laurence Knott
Current Version:
Peer Reviewer:
Prof Cathy Jackson
Last Checked:
15/10/2013
Document ID:
2577 (v26)
© EMIS

Common searches for this page include: What is erythema infectiosum